SkinBioTherapeutics Enhances Share Capital
Company Announcements

SkinBioTherapeutics Enhances Share Capital

SkinBioTherapeutics (GB:SBTX) has released an update.

SkinBioTherapeutics, a company dedicated to skin health, has announced the conversion of £100,000 in convertible bonds into over 1.1 million ordinary shares, following a notice from Macquarie. These new shares are to be admitted to AIM, raising the company’s total issued shares and voting rights to 203,372,037. This strategic financial move is part of the company’s ongoing efforts to advance its skin healthcare technology and product offerings, including a supplement for psoriasis.

For further insights into GB:SBTX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskSkinBioTherapeutics Voting Rights Shift Slightly
TipRanks UK Auto-Generated NewsdeskSkinBioTherapeutics Expands with Strategic Acquisitions and Growth
TipRanks UK Auto-Generated NewsdeskSkinBioTherapeutics Gains Increased Stakeholder Interest
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App